PRP should be prepared allogenically by collecting a total of 8 ml of venous blood from the arm into a
sterile citrated PRP tube. After centrifuging at +4°C and 2500 rpm for 8 minutes, the lower 1/3 of the plasma
in the tube is drawn into a 2.5 ml syringe and a total of 1 ml of PRP is obtained. Then, 0.5 ml of
erythropoietin is added to the same syringe (For Non Exudative AMD). A total of 1.5 ml of the solution of the
citrate, exosomes and erythropoietin mixture is injected into the subtenon space. This process is repeated
for 3 sessions in 2 months between 1 month interval. Platelet-rich plasma (PRP) containing neurotrophins
neurotrophic growth factors to increase the neural methabolism and reactivating the dormant
photoreceptors. Erithropoietin increase the neuroal capillary density and blood flow. Electromagnetic
iontophoresis (MagnoVisionTM) is essential for growth factors and molecules injected into the sub-tenon
space to pass into the sub-retinal space. MagnoVision also facilitates the passage of these systemic drug
molecules across the blood retina barrier. Omega3 (DHA and EPA) are essential for the phospholipid
structure of photoreceptor membranes. Lutein is the pigment required for the metabolism of rod cells.
Zeoxanthine is the pigment required for the metabolism of cone cells. Coenzyme Q ensures the removal of
drusens from the microenvironment through autophagy and ensures hemostasis. Exosome levels in
peripheral blood decrease with age. Therefore, PRP should be obtained allogeneically from a young healthy
donor.